For instance, a clinical trial of 11,000 people found that using GLP-1 RAs reduced kidney disease progression by 18%, kidney failure by 16% and risk of cardiac events by 13%
Xianyu YL, Xie YZY, Wang NX, Wang Z, Jiang XY
Public understanding of endometriosis: Findings from a UK-based qualitative study
& Arjmand, M
It inhibited NO, PGE-2 and proinflammatory cytokines (TNF-, IL-1 and IL-6) while reducing ROS production and NADPH oxidase activation
Administration : Injectable, once weekly Mechanism : Triple GLP-1, GIP, and glucagon receptor agonist Efficacy : Up to 2224% weight loss at 48 weeks Significant metabolic and glycemic improvements Safety : Higher rates of GI side effects and dose-related heart rate increases For patients needing maximum weight loss , Retatrutide leads the packbut at the cost of potentially more side effects